DiscoveryProbe™ FDA-approved Drug Library: Redefining Drug Repositioning Through Functional Genomics

Introduction: The Evolving Landscape of Drug Discovery

Advances in high-throughput screening and functional genomics have dramatically accelerated the pace and scope of modern drug discovery. While traditional strategies often focused on de novo compound synthesis and mechanism-based design, the increasing availability of FDA-approved bioactive compound libraries has transformed the paradigm, enabling rapid drug repositioning, target deconvolution, and pathway elucidation. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) stands at the forefront of this revolution, offering researchers an expertly curated, ready-to-screen collection of 2,320 clinically validated molecules tailored for high-throughput and high-content applications. In this article, we offer a differentiated perspective: examining how the DiscoveryProbe™ library, when integrated with functional genomic platforms, uniquely empowers drug repositioning and pharmacological target identification in complex disease contexts such as sarcopenia, cancer, and neurodegeneration.

Mechanistic Foundation: The Composition and Utility of the DiscoveryProbe™ Library

Curated Diversity for Mechanistic Breadth

The DiscoveryProbe™ FDA-approved Drug Library comprises 2,320 bioactive compounds that have received regulatory approval from global authorities including the FDA, EMA, HMA, CFDA, and PMDA, or are listed in leading pharmacopeias. This extensive library covers a broad landscape of mechanisms of action:

• Receptor agonists/antagonists (e.g., beta-blockers, opioid modulators)
• Enzyme inhibitors (e.g., kinase inhibitors, protease inhibitors)
• Ion channel modulators (e.g., calcium channel blockers)
• Signal pathway regulators (e.g., mTOR, NF-κB pathway modulators)

Representative compounds such as doxorubicin, metformin, and atorvastatin highlight the library’s clinical relevance and mechanistic breadth. Each compound is supplied as a 10 mM solution in DMSO, available in multiple formats (96-well microplates, deep-well plates, or 2D barcoded tubes) and is stable for up to 24 months at -80°C. This ready-to-use format is ideal for streamlining high-throughput screening (HTS) and high-content screening (HCS) workflows, especially in settings where assay robustness and reproducibility are paramount.

Beyond Conventional Screening: Integrating Functional Genomics for Drug Repositioning

Why Functional Genomics?

Whereas previous reviews of the DiscoveryProbe™ library have focused on live-cell screening and pathway analysis—such as the detailed exploration of mTOR signaling in Unlocking Live-Cell Pathways—this article delves deeper into the synergy between bioactive compound libraries and genomic-scale screening. Functional genomics, encompassing CRISPR-Cas9 knockouts, transcriptomic profiling, and epigenetic mapping, provides an unbiased platform to dissect the cellular consequences of drug exposure, uncovering both on-target and off-target effects. When paired with the DiscoveryProbe™ FDA-approved Drug Library, these approaches offer several unique advantages:

• Unbiased Target Identification: Genome-wide screens can reveal unanticipated molecular targets and signaling networks modulated by approved drugs.
• Phenotype-to-Mechanism Mapping: Integration of cellular phenotypes (e.g., changes in differentiation, apoptosis, or metabolism) with transcriptomic or proteomic data enables the tracing of compounds’ effects to specific gene networks.
• Accelerated Drug Repositioning: Approved drugs demonstrating activity in novel genomic contexts can be prioritized for rapid preclinical or clinical evaluation, reducing development timelines and costs.

Case Study: Sulfasalazine as a Repositioned Therapeutic for Sarcopenia

Functional Genomics-Guided Discovery

The real-world power of this approach was recently exemplified in a study on sarcopenia, a debilitating condition characterized by progressive muscle atrophy (see Park et al., Experimental Gerontology 2025). In this investigation, researchers leveraged an FDA-approved drug library to screen for compounds that modulate the PHF20–YY1 transcriptional axis, a key regulator of muscle differentiation and atrophy. Using a PHF20-induced YY1 promoter luciferase assay in C2C12 myoblasts, the team identified sulfasalazine—a well-known anti-inflammatory agent—as a potent inhibitor of PHF20-driven YY1 activity (IC50 = 24 μM).

Mechanistically, sulfasalazine suppressed YY1 expression and enhanced the transcription of muscle-specific genes, promoting myogenic differentiation both in vitro and in mouse models of muscle atrophy. Moreover, clinical data from patients with inflammatory bowel disease (IBD) treated with sulfasalazine revealed preserved skeletal muscle mass, supporting the compound’s repositioning potential for sarcopenia—a condition with no currently approved therapies. This example demonstrates the critical role of high-content screening drug libraries, such as DiscoveryProbe™, in rapidly bridging genomic insights with therapeutic innovation.

Integrative Pathway Analysis and Signal Regulation

Beyond identifying single-agent effects, combining the DiscoveryProbe™ FDA-approved Drug Library with functional genomics enables systematic mapping of drug–gene–pathway relationships. In the sulfasalazine study, for example, network analysis linked NF-κB inhibition to YY1 transcriptional repression, highlighting how signal pathway regulation can be functionally dissected using validated compound collections and multi-omic readouts.

Differentiation: Advancing Beyond Existing Approaches

While existing articles have extensively detailed the DiscoveryProbe™ library’s utility in mechanistic pathway studies and translational workflows—such as the comprehensive strategies for translational researchers discussed in From Mechanistic Insight to Translational Impact—the current article distinguishes itself by focusing on the integration of functional genomics with compound screening. Rather than centering exclusively on live-cell readouts, necroptosis inhibition, or competitive landscape mapping, we highlight how the combination of genomic perturbation and pharmacological screening uniquely accelerates:

• Drug repositioning screening for underexplored indications (e.g., sarcopenia, metabolic disorders)
• Pharmacological target identification in complex, multi-genic diseases
• Network-based dissection of drug mechanism-of-action, including enzyme inhibitor screening and modulation of noncanonical pathways

In contrast, for example, Unveiling Mechanistic Drug Discovery emphasizes necroptosis inhibition and translational strategies, while our perspective is more integrative—bridging functional genomics, high-content screening, and multi-omic analysis for deeper biological insights.

Advanced Applications: Beyond Oncology and Neurodegeneration

Cancer and Neurodegenerative Disease Drug Discovery

The value of this approach extends well beyond muscle biology. In oncology, combining the DiscoveryProbe™ FDA-approved Drug Library with CRISPR-based synthetic lethality screens enables the rapid identification of drug–gene interactions that sensitize tumor cells or overcome resistance. For neurodegenerative diseases, integrating transcriptomic profiling with high-content screening compound collections can reveal novel regulators of neuronal survival, synaptic function, or protein aggregation. Such integrative approaches have the potential to uncover unanticipated therapeutic avenues in Alzheimer’s, Parkinson’s, and ALS, providing new hope for diseases with limited treatment options.

Metabolic Diseases, Immunology, and Precision Medicine

Emerging applications also include metabolic disease modeling—where single-cell RNA sequencing combined with FDA-approved compound libraries helps define metabolic pathway vulnerabilities—as well as immunomodulation, where functional genomics can identify drugs that selectively reprogram immune cell states. In the era of precision medicine, this workflow can be tailored to patient-derived cellular models, enabling the discovery of repositioned drugs that target patient-specific genomic or epigenetic alterations.

Comparative Analysis: Advantages Over Alternative Methods

Compared to de novo compound libraries or fragmented collections, the DiscoveryProbe™ FDA-approved Drug Library offers several distinctive advantages for advanced screening paradigms:

• Clinical Relevance: Every compound is already approved or recognized in major pharmacopeias, facilitating rapid translation and lowering toxicity risk.
• Mechanistic Diversity: The library encompasses a wide spectrum of pharmacological classes, supporting broad mechanism-of-action studies and enzyme inhibitor screening.
• Optimized Format: Pre-dissolved 10 mM DMSO solutions in flexible plate or tube formats ensure assay reproducibility and high-throughput compatibility.
• Stability and Logistics: Long-term storage at -80°C (up to 24 months) and shipping options tailored for HTS/HCS platforms streamline operational workflows.

When integrated with functional genomics, these features uniquely position the DiscoveryProbe™ library for state-of-the-art drug repositioning and pharmacological target identification—an approach that complements, but goes beyond, the operational bottleneck solutions outlined in Translational Acceleration in the Era of Mechanistic Precision.

Conclusion and Future Outlook

The convergence of high-throughput screening drug libraries and functional genomics marks a paradigm shift in drug discovery and repositioning. The DiscoveryProbe™ FDA-approved Drug Library exemplifies this transformation, offering a comprehensive, clinically validated compound collection optimized for next-generation screening and multi-omic integration. As demonstrated by the rapid repositioning of sulfasalazine for sarcopenia (see Park et al., 2025), the synergy between compound libraries and genomic technologies enables the unbiased discovery of mechanistic insights, therapeutic targets, and repositioned drugs across diverse disease landscapes.

Future directions will likely include the expansion of compound diversity, the integration of artificial intelligence for predictive screening, and the deployment of patient-specific cellular models to further personalize drug discovery. By embracing this integrative approach, researchers are poised to unlock new frontiers in signaling pathway regulation, enzyme inhibitor screening, and beyond—ushering in a new era of precision therapeutics.